EAN News

EAN President Paul Boon looks back at the 9th Congress of the European Academy of Neurology, which took place in Budapest on 1-4- July.

Our paper of the month is a phase 3, double-blind, multicentre, trial investigating the efficacy and the safety of vorasidenib, a dual inhibitor of the IDH1 and IHD2 enzymes, in patients with residual or recurrent IDH mutant grade 2 gliomas.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for July 2023.

World Brain Day is an annual event observed on July 22, aimed at promoting awareness and education for neurological disorders that affect individuals worldwide. In 2023, a key focus of World Brain Day is on Brain Health and Disability. It… Continue Reading

All neurologists interested in learning more about mentorship are invited to join this highly informative and interactive workshop at EAN 2023, hosted by two members of the EAN Mentorship Task Force.

Programme Committee Chair, Ulf Kallweit, provides a preview of the 9th Annual Congress of the European Academy of Neurology, in Budapest on 1-4 July.

This month we have selected two papers of the month, reporting the results of two randomised, double-blind, placebo-controlled, phase III trials investigating potential therapies for generalised Myasthenia Gravis.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for June 2023.

One full bursary and three free registrations are yours to be won by participating in our survey on general neurology.

Co-Chair of the EAN Scientific Panel on Dementia and Cognitive Disorders answers three key questions about a groundbreaking Alzheimer study.

We are happy to announce that our Sustainability Report 2023 is ready to be downloaded via the new Sustainability page of EAN.org.

Watch a full recording of the European Brain Health Summit 2023, held on 9 May, featuring key international voices on precision neurology and the prevention of neurological diseases.

EAN Scientific Committee Chair, Thomas Berger, reports on the new Cost-Conscious Healthcare project, the EAN Science School, and how EAN members can play a part in setting the EAN's scientific course.

Our paper of the month is a phase 1b, randomised, multicentre, placebo-controlled trial, which aims to investigate the safety, pharmacokinetics, and effects of MAPTRx in patients with mild Alzheimer's.

EAN President, Paul Boon, on the forthcoming Brain Health Summit, EAN advocacy activities, the recent national societies forum, and more.